Subject: Dr. Amin Tamadon
From: "http://gsia.sums.ac.ir/"

Shiraz University of Medical Sciences - SUMS 
Code : 18911      Publish Date : Monday, June 15, 2020 Visit : 1522 

Dr. Amin Tamadon 

Dr. Amin Tamadon 

	 Dr. Amin Tamadon

Professor

Regenerative Medicine

School of Public Health, Dentistry, Pharmacy and Nursing

Department of Natural Sciences

West Kazakhstan Marat Ospanov Medical University

Aktobe, Kazakhstan

E-mail Address: [email-masked]

Phone: +7 (7132) 56-34-25

Address: Maresyev St, Aktobe 030012, Kazakhstan

CV

 

Biography 

Dr. Amin Tamadon earned his DVM from Shiraz University, Iran (2005) and
a PhD in Veterinary Obstetrics and Reproductive Diseases from the same
institution (2010). He pursued Postdoctoral fellowships at Seoul
National University, South Korea (2015) and Fudan University, China
(2017). Currently, Dr. Tamadon serves as the Professor and Principal
Investigator of Regenerative Medicine at West-Kazakhstan Marat Ospanov
Medical University and is the founder of PerciaVista R&D Co.,
specializing in stem cell therapy.

Research Priorities:

Our collaboration with Shiraz University of Medical Sciences (SUMS)
focuses on advancing stem cell therapy, particularly mesenchymal stem
cells (MSCs) and exosome therapy, for various diseases. We aim to
exchange PhD and postdoc students, conduct collaborative projects, and
potentially commercialize therapies.

Stem Cell Research Focus: MSCs and Exosome Therapy

MSCs, multipotent cells with immune-modulating properties, hold promise
for regenerative medicine. Our priorities include developing MSC
isolation protocols, studying their differentiation potential, and
exploring their immunomodulatory effects. We also aim to investigate
the therapeutic potential of MSC-derived exosomes, focusing on their
isolation, characterization, and mechanisms of action in tissue repair
and immunomodulation.

We propose a student exchange program to enhance collaboration.
Students will receive training in stem cell and exosome research,
participate in joint projects, and benefit from mentorship and
networking opportunities.

Our joint projects will focus on disease modeling, clinical trials, and
biomarker discovery. We aim to develop disease models, conduct
preclinical and clinical trials, and identify biomarkers for monitoring
treatment response.

To translate our research into therapies, we plan to protect
intellectual property, form industry partnerships, and support startup
creation. This will ensure the commercial viability of MSC and
exosome-based therapies.

Previous Academic Collaborations with SUMS:

*	Publication of more than 70 articles with SUMS affiliation.
*	Performing more than 20 research projects.
*	Collaboration in establishment of 2 labs and 1 research center
at SUMS.

Number and Duration of Previous Visits to SUMS:

None